Gathering patients’, carers’ and doctors’ opinions on the use of blood tests to monitor the treatment of oesophageal, stomach and bowel cancers- a qualitative study

Not Applicable

Recruiting

• Conditions: Bowel cancer; Stomach cancer; Oesophageal cancer; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Cancer - Bowel - Back passage (rectum) or large bowel (colon); Cancer - Oesophageal (gullet); Cancer - Stomach; Public Health - Health service research

• Registration Number: ACTRN12622000100796
• Lead Sponsor: Flinders Medical Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-01-24
• Last Update Posted: 5 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Participants, carers and clinicians who fit the following criteria will be invited into the study:
1)be over 18 years of age and be willing to participate in a focus group either in person at the Flinders Centre for Innovation in Cancer (Bedford Park, South Australia), or be able to participate in group discussion via a web-based format e.g. Microsoft Teams or Zoom.
2)have undergone treatment (within the previous 3 years) of stomach, oesophageal or bowel cancer, OR have supported someone who has a history of one of these cancers, OR work in a clinical role providing clinical care for patients with these cancers.

Exclusion Criteria

Participants will be excluded if:
1)They are in the palliative phase of their cancer;
2)Have any underlying conditions (e.g., anxiety/depression) where discussing their diagnosis and treatment might exacerbate any symptoms.
Participants, carers or clinicians will be excluded if:
1)They have a perceived or actual conflict of interest relating to any blood biomarker tests.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Knowledge of clinical tests to monitor cancer treatment and surveillance, which will be assessed using qualitative, audio recorded, 45-minute focus group discussions which will be semi-structured based upon a study-specific discussion guide.[ 1 month after recruitment (during the focus group)];Trust in clinical tests to monitor cancer treatment and surveillance, which will be assessed using qualitative, audio recorded, 45-minute focus group discussions which will be semi-structured based upon a study-specific discussion guide.[ 1 month after recruitment (during the focus group)];Experience of clinical tests to monitor cancer treatment and surveillance, which will be assessed using qualitative, audio recorded, 45-minute focus group discussions which will be semi-structured based upon a study-specific discussion guide.[ 1 month after recruitment (during the focus group)]

Secondary Outcome Measures

Name	Time	Method
Perspectives on specific blood-based biomarker, which will be assessed using qualitative, audio recorded, 45-minute focus group discussions which will be semi-structured based upon a study-specific discussion guide.[ 1 month after recruitment (during the focus group)]